Last reviewed · How we verify
Dibismuth trioxide
Dibismuth trioxide, marketed by National Taiwan University Hospital, holds a unique position in its therapeutic area with no direct competitors listed. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. However, the lack of detailed revenue and trial results poses a significant risk in assessing its long-term commercial viability and efficacy.
At a glance
| Generic name | Dibismuth trioxide |
|---|---|
| Also known as | KCB F.C., bismuth |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males (PHASE4)
- The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication (PHASE4)
- Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP (PHASE3)
- Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection (PHASE4)
- Sequential Versus Quadruple Therapy in the Second-line Treatment (PHASE4)
- Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dibismuth trioxide CI brief — competitive landscape report
- Dibismuth trioxide updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI